香港市場銘柄情報

09989 海普瑞薬業

銘柄追加

3.530
+0.170+5.06%

寄付前 05/02 16:08 CST

51.80億時価総額-6762直近PER

海普瑞薬業に関するコメント

ログインコメントを投稿

Moomoo AI

02/04 10:01

Shenzhen Hepalink Pharmaceutical Group's P/E remains high despite price drop, justified by superior earnings outlook. Investors see low risk of earnings deterioration, providing strong share price support.

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SZSE:002399) Stocks Pounded By 35% But Not Lagging Market On Growth Or Pricing

Moomoo AI

01/17 07:23

The market's muted reaction to the company's declining EPS and share price might be due to expectations of a business turnaround. However, the company's poor performance last year and long-term share price weakness could indicate unresolved challenges.

Investors Five-year Losses Continue as Shenzhen Hepalink Pharmaceutical Group (SZSE:002399) Dips a Further 5.9% This Week, Earnings Continue to Decline

Moomoo AI

2023/12/21 20:21

Investors overlook limited growth potential of Shenzhen Hepalink, increasing risk of future disappointment if P/S ratio aligns with growth outlook. A hike in future revenue projections may justify current P/S ratio.

Unpleasant Surprises Could Be In Store For Shenzhen Hepalink Pharmaceutical Group Co., Ltd.'s (SZSE:002399) Shares

Moomoo AI

2023/12/21 20:04

Shenzhen Hepalink's limited growth potential seems overlooked by investors buying the stock, risking future disappointment when the P/S ratio aligns with growth outlook. Analysts hope for a positive shift in future revenue forecasts to justify current price-to-sales ratio.

Unpleasant Surprises Could Be In Store For Shenzhen Hepalink Pharmaceutical Group Co., Ltd.'s (SZSE:002399) Shares

Moomoo AI

2023/12/21 19:53

Shenzhen Hepalink's limited growth outlook is ignored by investors optimistic about its stock, creating a risky scenario if future revenue projections do not match its current price-to-sales ratio.

Unpleasant Surprises Could Be In Store For Shenzhen Hepalink Pharmaceutical Group Co., Ltd.'s (SZSE:002399) Shares

Moomoo AI

2023/12/21 19:51

Investors may face disappointment as Shenzhen Hepalink's limited growth clashes with its high P/S ratio. Analysts require a positive shift in future revenue forecasts to justify the current valuation.

Unpleasant Surprises Could Be In Store For Shenzhen Hepalink Pharmaceutical Group Co., Ltd.'s (SZSE:002399) Shares

まだコメントはありません

分析

アナリスト評価

データなし

目標株価

データなし

ホット

香港株

総合人気